Walgreens Tops Wall Street Expectations as Drugstore Chain Continues Turnaround Plan
Generado por agente de IAMarcus Lee
viernes, 10 de enero de 2025, 8:52 am ET1 min de lectura
COLD--
Walgreens Boots Alliance, Inc. (WBA) has reported better-than-expected fiscal first quarter earnings, signaling progress in its ongoing turnaround plan. The drugstore chain, which has been grappling with shrinking prescription reimbursement, rising costs, and other challenges, announced a plan in October to close around 1,200 locations. The company's shares jumped 16% in early morning trading on Friday, marking a better start than the stock had last year.
Walgreens reported adjusted earnings per share of 51 cents, excluding store closing costs, which was higher than analysts' expectations of 38 cents per share. Revenue grew 7.5% to $39.5 billion, surpassing the expected $37.4 billion. The company's main business, established U.S. retail pharmacies, saw sales grow more than 8%, driven by a jump in prescriptions. This countered a drop in sales for the retail area outside store pharmacies, partly due to a weaker cough, cold, and flu season.
The company also saw growth from its U.S. health care business, which it has been scaling back. Walgreens reaffirmed its forecast for fiscal 2025 adjusted earnings per share ranging between $1.40 and $1.80, with analysts forecasting earnings of $1.52 per share.
Walgreens' turnaround plan includes closing underperforming stores and focusing on its most profitable locations. The company expects the store closures to be immediately accretive to adjusted EPS and free cash flow. By realigning its footprint to a healthier store base, Walgreens aims to respond more dynamically to shifts in consumer behavior and buying preferences.
The company's U.S. healthcare segment is another key driver of growth. In the fiscal first quarter, the segment saw strong revenue growth, with VillageMD revenue growing 7% to bring in $1.5 billion. Walgreens is also reviewing its U.S. healthcare business, including its VillageMD clinic business, and may consider selling all or part of it. This strategic review is part of the company's efforts to focus on its core competencies and improve its long-term growth prospects.

Walgreens' turnaround plan is a critical step in addressing the challenges faced by the drugstore chain. By closing underperforming stores, focusing on its most profitable locations, and exploring strategic partnerships or divestments in its healthcare services, Walgreens aims to create a more sustainable and profitable business model for the future.
Investors should monitor Walgreens' progress in implementing its turnaround plan, as well as the company's financial performance and growth prospects. By focusing on key performance indicators such as store closures, revenue growth, adjusted earnings per share, operating cash flow, and the performance of its U.S. healthcare segment, investors can better evaluate Walgreens' turnaround progress and make more informed decisions about the company's stock.
WBA--
Walgreens Boots Alliance, Inc. (WBA) has reported better-than-expected fiscal first quarter earnings, signaling progress in its ongoing turnaround plan. The drugstore chain, which has been grappling with shrinking prescription reimbursement, rising costs, and other challenges, announced a plan in October to close around 1,200 locations. The company's shares jumped 16% in early morning trading on Friday, marking a better start than the stock had last year.
Walgreens reported adjusted earnings per share of 51 cents, excluding store closing costs, which was higher than analysts' expectations of 38 cents per share. Revenue grew 7.5% to $39.5 billion, surpassing the expected $37.4 billion. The company's main business, established U.S. retail pharmacies, saw sales grow more than 8%, driven by a jump in prescriptions. This countered a drop in sales for the retail area outside store pharmacies, partly due to a weaker cough, cold, and flu season.
The company also saw growth from its U.S. health care business, which it has been scaling back. Walgreens reaffirmed its forecast for fiscal 2025 adjusted earnings per share ranging between $1.40 and $1.80, with analysts forecasting earnings of $1.52 per share.
Walgreens' turnaround plan includes closing underperforming stores and focusing on its most profitable locations. The company expects the store closures to be immediately accretive to adjusted EPS and free cash flow. By realigning its footprint to a healthier store base, Walgreens aims to respond more dynamically to shifts in consumer behavior and buying preferences.
The company's U.S. healthcare segment is another key driver of growth. In the fiscal first quarter, the segment saw strong revenue growth, with VillageMD revenue growing 7% to bring in $1.5 billion. Walgreens is also reviewing its U.S. healthcare business, including its VillageMD clinic business, and may consider selling all or part of it. This strategic review is part of the company's efforts to focus on its core competencies and improve its long-term growth prospects.

Walgreens' turnaround plan is a critical step in addressing the challenges faced by the drugstore chain. By closing underperforming stores, focusing on its most profitable locations, and exploring strategic partnerships or divestments in its healthcare services, Walgreens aims to create a more sustainable and profitable business model for the future.
Investors should monitor Walgreens' progress in implementing its turnaround plan, as well as the company's financial performance and growth prospects. By focusing on key performance indicators such as store closures, revenue growth, adjusted earnings per share, operating cash flow, and the performance of its U.S. healthcare segment, investors can better evaluate Walgreens' turnaround progress and make more informed decisions about the company's stock.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios